Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35

Breaking Down the Cost of Healthcare: Medicare Beneficiaries to Reap Benefits from Falling Drug Prices The rising cost of prescription medications has been a pressing concern for many Americans, particularly

Image source: The Motley Fool. Date Saturday, Nov. 8, 2025 at 12:16 p.m. ET Call participants Chief Commercial Officer — Dan Dischner Chief Financial Officer and Executive Vice President of

Image source: The Motley Fool. DATE Wednesday, Oct. 1, 2025 at 12:22 p.m. ET CALL PARTICIPANTS President and CEO — Sherman Miller Chief Financial Officer — Max Bowman Need a

Image source: The Motley Fool. DATE Thursday, Oct. 23, 2025 at 1:37 p.m. ET CALL PARTICIPANTS President — August Troendle CFO — Kevin Brady Investor Relations — Jesse Geiger Investor

Image source: The Motley Fool. Date Tuesday, Nov. 4, 2025 at 7:26 p.m. ET Call participants Chief Executive Officer — Joseph K. Belanoff Chief Business Officer — Gary Robb President,

Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its blockbuster obesity drug, Wegovy (injectable semaglutide). The FDA filing seeks approval

Its involvement often leads to distortions and perverse incentives. Dr. Gilberto de Lima Lopes Jr. is right that the market for medications is imperfect, but it is often government that

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized as the

Diagnostics, Vol. 15, Pages 3025: Beyond BMI: Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine Diagnostics doi: 10.3390/diagnostics15233025 Authors: Maria-Daniela Tanasescu Andrei-Mihnea Rosu Alexandru Minca Andreea-Liana

JCM, Vol. 14, Pages 8413: Epicardial Fat and Heart Failure in Type 2 Diabetes: Metabolism, Imaging and Novel Biomarkers—A Translational Perspective Journal of Clinical Medicine doi: 10.3390/jcm14238413 Authors: Pedro Gil-Millan

For individuals taking GLP‑1 medications such as Ozempic, Thanksgiving doesn’t have to be restrictive, but specific foods and beverages need caution. Dietitian Kylie Bensley recommends avoiding mac and cheese, candied

submitted by /u/Cough_Geek [link] [comments]

GLP-1 receptor agonists affect sexual function differently across individuals and influencing libido and hormone levels in men and women during treatment. Medscape News Europe

(MedPage Today) — GLP-1 receptor agonist use was associated with chronic cough regardless of a previous gastroesophageal reflux disease (GERD) diagnosis, a study of over 2 million people with type

A wave of vital prescription drugs is about to get a lot cheaper for people on Medicare. The Trump administration announced Tuesday that it has successfully negotiated lower prices for

Comments

Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it

U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. speaks during the Western Governors’ Association meeting Thursday, Nov. 20, 2025, in Scottsdale, Ariz. (AP Photo/Rebecca Noble) 2025-11-26T17:21:00Z NEW

HMM: Stopping GLP-1 drugs before pregnancy linked to complications. “Women who stop taking a GLP-1 weight loss/diabetes medication just prior to a pregnancy appear to be at higher odds for

Indian drugmakers are adjusting prices for weight-loss injections. Novo Nordisk has cut prices for its drug Wegovy. This move is prompting generic companies to lower their expected launch prices. Novo

The new negotiated prices for Novo Nordisk’s GLP-1 drugs under the Inflation Reduction Act have raised questions about how they will impact the prices Novo agreed to under its separate

Former first lady Michelle Obama looks ultra-thin these days, leading just about everyone to speculate she’s joined the growing number of Americans who are taking Ozempic or a similar prescription

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of the program’s price negotiations, touting a total of $12

From reducing reliance on Chinese APIs to expanding innovation in biologics and next-generation therapies like GLP-1 agonists for obesity and diabetes, the sector is moving beyond its generics-driven legacy into

Health Why childhood obesity endures, grows Issues are complex, touch on lifestyle, culture, genetics, economy, policy Alvin Powell Harvard Staff Writer November 26, 2025 long read Steve Gortmaker. Veasey Conway/Harvard

Ozempic can cost anywhere from over $1,000 to a $25, depending on how you pay for it. Peter Dazeley/Getty Images Colon cancer patients taking GLP-1 drugs, like Ozempic, had better

Price are falling sharply for Medicare beneficiaries prescribed Novo Nordisk’s GLP-1 drugs like Ozempic in 2027.

Millions of Americans on GLP-1 weight loss drugs are navigating Thanksgiving differently this year. Some are delaying injections to enjoy the holiday feast with a restored appetite, while others are

While being on a GLP-1 can help to accelerate weight loss and regulate blood sugar, it also has the potential to change how people interact socially. As the holidays approach,

Larry Humphreys, a retired Federal Emergency Management Agency worker in Moultrie, Georgia, says he and his wife won’t be traveling much next year after their monthly health insurance premium payment

submitted by /u/Hrmbee [link] [comments]

Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds  The New York Times The complicated relationship between GLP-1s and pregnancy  The Washington Post Study links GLP-1 use to some pregnancy risks

The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t

Dr Terry Dubrow announced a new Ozempic-related disorder, which he called ‘Ozempic penis,’ where one’s member ‘looks bigger’ while taking the GLP-1 medication.

The government on Tuesday announced final prices for the second round of drugs negotiated by Medicare under the Inflation Reduction Act, including for Novo Nordisk’s blockbuster weight loss drugs Ozempic

By mid-2024, the weight-loss drugs were prescribed for almost 2 percent of new mothers.

There have been some interesting failures recently in Alzheimer’s trials. As long-time readers will know, I consider basically all Alzheimer’s drug trials to have failed to one degree or another,

Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled

Women who stop taking GLP-1 medications just prior to a pregnancy appear to be at higher odds for weight gain and complications, researchers said.

Publication date: 2 December 2025 Source: JACC, Volume 86, Issue 22 Author(s): Erica S. Spatz

As more consumers take weight loss medications like Ozempic or Wegovy, companies will need to act fast if they want to adapt, according to Circana.

Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release

We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying.

We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Costco Wholesale Corp (NASDAQ:COST) is one of the top non-AI stocks redditors are buying. Redditors

NATICK, Mass.–(BUSINESS WIRE)—- $ALUR–Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program

Image source: The Motley Fool. Date Tuesday, Nov. 25, 2025 at 8 a.m. ET Call participants Chief Executive Officer — Devdatt Kurdikar Chief Financial Officer — Jacob P. Elguicze Need

Gut health, GLP-1 and AI – the issues shaping ingredients and NPD  Yahoo

By Ernie Mundell HealthDay ReporterTUESDAY, Nov. 25, 2025 (HealthDay News) — Women who stop taking a GLP-1 weight loss/diabetes medication just…

By Ernie Mundell HealthDay ReporterTUESDAY, Nov. 25, 2025 (HealthDay News) — New clinical trial results bode well for what could be the first GLP-1…

Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability. OXFORD, England and PORTLAND, ME, Nov. 25, 2025 /PRNewswire/ — Ovation.io, a

Two major clinical disappointments Johnson & Johnson’s anti-tau antibody and Novo Nordisk’s GLP-1 metabolic therapy underscore just how complex and Alzheimer’s remains.

At the Next Generation Ingredients 2025 conference, speakers from across the industry explored how health innovation and ethical sourcing are shaping consumer expectations. The post Gut health, GLP-1 and AI

Cornell University-led study evaluates novel protein therapy designed to help cats achieve a healthier body condition with convenient once-a-week dosing BEVERLY, Mass., Nov. 25, 2025 /PRNewswire/ — Akston, the Biotech

Illustrations by Lucas Burtin Sometimes I think I became a mother not in a hospital room but in a Trader Joe’s in New York City. It was May 2020. A

Hello there and happy Tuesday from STAT’s London outpost, with Andrew Joseph here filling in for Mr. Pharmalot for the day. While it feels like things are slowing down stateside

Salty meals can lead to high blood pressure, the cause of a wide variety of other health conditions. Hypertension, also known as high blood pressure, is a silent killer that

I started on a GLP1 med a couple weeks ago for weight management and so far its helping with appetite but im dealing with some fatigue and mild nausea that

Abstract Aims Published literature has raised concerns regarding a causal association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated

Former US first lady, Michelle Obama has sparked Ozempic weight loss rumors after she showed off a seemingly slimmer figure in a new photoshoot. Obama, 61, posed in the new shoot by

Novo Nordisk shares dropped 12% after the company announced that semaglutide, the GLP-1 drug behind Ozempic and Wegovy, failed to show any benefit in slowing cognitive decline in early Alzheimer’s

Michelle Obama shared photos from a shoot with Annie Leibovitz, sparking baseless speculation about weight-loss medication. While some online users theorized about her appearance, Obama has previously discussed natural changes

In recent years, we’ve seen the conversation around obesity slowly change. For all of modern history, obesity has been treated like a lifestyle decision, the result of poor choices from

$NVO Faces Market Pressure Follow by Alzheime Clinical Trial Novo Nordisk A/S Sponsored ADR Class B BATS:NVO KalaGhazi Shares of Novo Nordisk (NYSE: NVO) found themselves among the session’s most

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer’s disease (AD), as two-year clinical trials end in disappointment for patients, medical scientists and drugmaker

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more

A new study hints that pregnant people who have previously taken drugs like Ozempic may face a higher risk of certain poor pregnancy outcomes. But more studies are needed to

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials  The New York Times Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says  CNN Novo Nordisk shares

PHOTO ART: MERCA2.0 The Economist published its traditional end-of-year special edition, The World Ahead 2026, an in-depth analysis projecting the key themes and trends that will reshape the global landscape

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.

The studies may still hold clues to the powers and limits of GLP-1 drugs

The complicated relationship between GLP-1s and pregnancy  The Washington Post Patients who discontinue GLP-1s found to have more weight gain, complications during pregnancy  Medical Xpress New Moms’ GLP-1 Prescriptions Jumped After Wegovy

Can GLP-1s treat vascular dementia? One study failed, but some researchers are holding out hope.

(MedPage Today) — The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer’s disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company

We knew the weight would return, but what happens to the other benefits when patients are no longer taking GLP-1 drugs? Medscape

(MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and higher risks of pregnancy complications, according to an analysis of

Researchers say a woman struggling with obesity who couldn’t resist eating fatty foods experienced declines in her cravings after taking tirzepatide.

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer’s progression

This paper advances a metabolic hypothesis that I certainly didn’t see coming. One of the great mysteries about alcoholism/alcohol use disorder is its underlying biochemical drivers. There’s obviously a behavioral

GLP-1s are helping Americans live better, but Washington has major work to do on safety. A lot has been happening this fall with the rocket ship rise of GLP-1 weight loss drugs. In September,

Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer’s — despite initial hopes that it might help against dementia. From

(MedPage Today) — Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for weight loss, a Danish epidemiological study found. In the first quarter

Seamus Fernandez, Guggenheim biotech analyst, joins ‘Power Lunch’ to discuss Novo Nordisk’s latest earnings results, if there’s a clear winner in the GLP-1 space and much more.

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more

Many people using GLP-1 weight loss drugs are seeing big changes during the holiday season. These medicines make people feel full faster, so Thanksgiving meals may feel different this year.

Key Points Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare. Lilly is close to

Strategy Investor behavior matters a lot when it comes to investing in ‘oddball funds.’ (morningstar.com) Bubbles are only obvious in hindsight. (ritholtz.com) Crypto How the Trump family fortune has been

Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have concluded without showing the desired clinical benefit. The manufacturer, Novo Nordisk, reported that

The use of glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, continues to climb amidst patient demand and a growing set of clinical indications for

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help combat neurodegeneration.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes such as miscarriage, congenital malformations,

This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.

This cohort study examines gestational weight gain and pregnancy outcomes after glucagon-like peptide-1 (GLP-1) receptor agonist discontinuation.

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24

Last week, Novo Nordisk NVO announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time price of $199 per month

Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants.  Eli